NICE now backs Sanofi's Jevtana

The U.K.'s NICE issued a final appraisal determination recommending Jevtana cabazitaxel from Sanofi (Euronext:SAN; NYSE:SNY) in combination with prednisone to treat metastatic hormone-relapsed prostate cancer in patients whose disease has progressed after receiving docetaxel.

In 2012, NICE issued guidance recommending against Jevtana's use because of concerns about its cost-effectiveness. Last year, NHS England removed the taxane derivative from the Cancer Drugs Fund (CDF), which is being integrated into NICE's appraisal process. ...